The results from clinical studies in patients with spinal cord injury and ALS demonstrated that treatment with anti-Nogo-A antibodies (administered intravenously or intrathecally) is safe and well-tolerated by patients [90,105]. Here, RTN4 is linked to amyotrophic lateral sclerosis.